AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02999334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Antenatal Care
Description: To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
Study NCT01005862 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: 10 mg/kg, single dose administered intravenously
Study NCT01005862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00856791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Baseline Survey
Description: The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Survey
Description: The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pre-intervention Survey
Description: Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-intervention Survey
Description: Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morally Congruent Message
Description: Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized.
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morally Non-Congruent Message
Description: Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized.
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Message
Description: Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Post-Intervention Survey
Description: Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
Study NCT02851459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-Intervention Survey
Description: Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
Study NCT01751750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Grape
Description: 16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
Study NCT03113669 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT-GSH
Study NCT00455000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: Monoclonal antibody
Study NCT00455000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03894839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glutaraldehyde disinfection and microwave application
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
Study NCT03894839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate disinfection and microwave application
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
Study NCT03894839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite disinfection and microwave application
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
Study NCT03894839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glutaraldehyde disinfection and ozone therapy
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
Study NCT03894839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate disinfection and ozone therapy
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
Study NCT03894839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite disinfection and ozone therapy
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
Study NCT02459197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heat Pain Stimuli A
Study NCT03804177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement with melatonin hyaluronic acid vit C
Description: immediate implant placement with melatonin and hyaluronic acid and systemic administration vitamin C
Study NCT03804177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement without melatonin hyaluronic acid vit C
Description: immediate implant placement without melatonin and hyaluronic acid and systemic administration vitamin C
Study NCT03693976 — intervention group
Intervention type: DRUG
Intervention: Xylometazoline Nasal Spray
Description: Application of Xylometazoline Nasal Spray in accordance with the instructions for use
Study NCT03693976 — intervention group
Intervention type: DEVICE
Intervention: Ectoin Rhinosinusitis Nasal Spray
Description: Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use
Study NCT01357122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCI Insertion
Description: DSAEK surgery will be performed using the NCI to insert the donor tissue.
Study NCT01357122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Forceps Insertion
Description: DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
Study NCT02102438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles.
Study NCT02102438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Paclitaxel
Description: Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
Study NCT02102438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
Study NCT04221464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological collection
Description: Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
Study NCT04221464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissues collections
Description: Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
Study NCT02459197 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Heat Pain Stimuli B
Study NCT02459197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Video
Study NCT02459197 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Video
Study NCT02459197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of T4P1001 capsules
Description: This treatment is given as add-on therapy to patient's regular analgesic treatment
Study NCT02459197 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Administration of Placebo capsules
Description: This treatment is given as add-on therapy to patient's regular analgesic treatment
Study NCT03130959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03130959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT03671876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention plus therapy
Description: Task oriented exercise plan to improve mobility for stroke patients
Study NCT04275258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan
Description: PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks.
Study NCT03015298 — intervention group
Intervention type: DEVICE
Intervention: PET/MRI
Description: The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
Study NCT03015298 — intervention group
Intervention type: DEVICE
Intervention: PET/CT
Description: At the next day of PET/MRI examination,A PET/CT examination will be performed.
Study NCT02817061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnilux
Description: The Omnilux LED array sources can be changed to emit different wavelength.
Study NCT02817061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Omnilux
Description: The Omnilux LED array sources can be changed to emit different wavelength.
Study NCT02858635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and neuropsychological assessment, Blood and saliva samples
Description: Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
Study NCT00198263 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Medpulser Electroporation with Bleomycin
Description: The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
Study NCT02196298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: 16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
Study NCT02196298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: 16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
Study NCT02416453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.
Study NCT02416453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
Study NCT02416453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
Study NCT04145700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab given IV
Study NCT04145700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine given IV
Study NCT03925129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency TENS treatment
Description: Treatment with high frequency for minimum of 1 hour after misoprostol administration
Study NCT03925129 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS treatment
Description: Treatment with sham TENS device for minimum of 1 hour after misoprostol administration
Study NCT04145700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine given IV
Study NCT04145700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel given IV
Study NCT04145700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given IV
Study NCT01802177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVB excimer light
Study NCT04215445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: Tab.empagliflozin 25mg once daily for 28 days
Study NCT04215445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-A
Description: Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.
Study NCT01011868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 placebo
Description: BI 10773 placebo
Study NCT01011868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 low dose
Description: BI 10773 low dose
Study NCT01011868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 high dose
Description: BI 10773 high dose
Study NCT01011868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 10773 placebo
Description: BI 10773 placebo
Study NCT00719329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 4.0%
Description: Solution (4.0%, 7.1% CHX-D)
Study NCT00719329 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dry Cord Care
Description: Educational messages regarding clean cord care
Study NCT04606498 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational study only - no intervention
Study NCT00936572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Probiotics (La1, BB536)
Study NCT00936572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotics (La1, BB536)
Study NCT00936572 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Maltodoxtrin
Study NCT04332159 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Closed nasal fracture reduction
Description: Closed nasal fracture reduction is performed under local anesthesia with addition of Methoxyflurane or placebo
Study NCT04332159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed nasal fracture reduction
Description: Closed nasal fracture reduction is performed under local anesthesia with addition of Methoxyflurane or placebo
Study NCT01867320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
Study NCT00570336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
Study NCT00570336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
Study NCT01957423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
Study NCT01957423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein
Description: Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
Study NCT00652704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate
Description: Capsules, 100 mg, fed
Study NCT00652704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monodox
Description: Capsules, 100 mg, fed
Study NCT00652704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate
Description: Capsules, 100 mg, fasting
Study NCT03209193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane use as main anesthetic drug during the surgery
Study NCT03209193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane use as main anesthetic drug during the surgery
Study NCT02541422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N Acetyl Cysteine
Study NCT02541422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03944213 — intervention group
Intervention type: DEVICE
Intervention: intermittent theta burst stimulation (iTBS)
Description: 20 sessions of iTBS
Study NCT03735082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 250mg,qd,d1-14,14day/cycle
Study NCT03735082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
Study NCT03735082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=4,d1,14day/cycle;
Study NCT03517241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional magnetic resonance imaging (fMRI)
Description: Retinotopic mapping using functional magnetic resonance imaging (fMRI) is based on MR images acquired with blood-oxygenation-level-dependent (BOLD) contrast to reveal areas of neuronal activity in the visual cortex
Study NCT03517241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microperimetry (MP)
Description: MP allows localized testing of retinal sensitivity of foveal, parafoveal and even more peripheral macular regions
Study NCT03517241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
Study NCT03517241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blue light fundus autofluorescence imaging (FAF)
Description: Fundus autofluorescence imaging (FAF), is a non-invasive diagnostic technique focusing on the fluorescent properties of pigments in the retina to generate images.